CollPlant Biotechnologies (CLGN) EBT (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly EBT came in at -$3.1 million in Q1 2026, down 89.02% YoY from -$28.4 million in Q1 2025, and up 90.26% on a QoQ basis from -$32.0 million in Q4 2025.
CollPlant Biotechnologies (CLGN) EBT (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of EBT data on file, last reported at -$3.1 million in Q1 2026.
- Quarterly EBT fell 89.02% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.4 million (down 421.98% YoY) and the FY2025 annual result came in at -$39.9 million, down 1.67% from the prior year.
- EBT climbed to -$3.1 million in Q1 2026, from -$32.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of $5.5 million in Q2 2023 to a low of -$32.0 million in Q4 2025.
- A 5-year average of -$4.2 million and a median of -$3.5 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT surged 231.52% — and 2025, when it sank 578.47%.
- Tracing CLGN's EBT over 5 years: stood at -$27.1 million in 2022, then soared by 81.49% to -$5.0 million in 2023, then grew by 6.15% to -$4.7 million in 2024, then slumped by 578.47% to -$32.0 million in 2025, then surged by 90.26% to -$3.1 million in 2026.
- The last three EBT figures came in at -$3.1 million (Q1 2026), -$32.0 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | -3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -3.12 Mn |
| Dec 31, 2025 | -31.98 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 30, 2025 | -1.65 Mn |
| Dec 31, 2024 | -4.71 Mn |
| Sep 30, 2024 | -4.50 Mn |
| Jun 30, 2024 | 4.07 Mn |
| Mar 31, 2024 | 4.20 Mn |
| Dec 31, 2023 | -5.02 Mn |
| Sep 30, 2023 | -4.72 Mn |
| Jun 30, 2023 | 5.50 Mn |
| Mar 31, 2023 | 3.24 Mn |
| Dec 31, 2022 | -27.14 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -4.19 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | -228.29 Mn |
| Sep 30, 2021 | 71.91 Mn |
| Jun 30, 2021 | -2.98 Mn |